bladder cancer Bavarian Nordic

Bavarian doses first patient in CV301 and atezolizumab Phase ll trial

Bavarian Nordic has dosed the first patient in a Phase ll trial to investigate CV301 in combination with atezolizumab (TECENTRIQ)…